Erasca stock plunges after patient death in cancer drug trial
Erasca, a biotech company, saw its stock drop nearly 50% following a patient death in a Phase 1/2 clinical trial of its cancer drug ERAS-0015. A 66-year-old male participant developed severe lung inflammation about one month after starting treatment and later died after withdrawing supportive care. The trial is evaluating ERAS-0015 for advanced solid tumors. The death has raised safety concerns, leading to a sharp decline in investor confidence.
Key facts
- Erasca stock sank almost 50% after a patient death in a cancer drug trial.
- A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015.
- The patient died after withdrawing supportive care.
- ERAS-0015 is being tested in a Phase 1/2 trial for advanced solid tumors.
- The trial is conducted by Erasca, a biotech company.
Entities
Institutions
- Erasca
Sources
- Quartz —